Yubo International Biotech Ltd

YBGJ OTC SEC CIK 895464
Follow Yubo International Biotech Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$188.4K +31.9% vs same quarter last year
EPS, diluted $0.00
Operating cash flow −$157 +99.9% vs same quarter last year
Revenue by quarter
$0
$0
$0
$12.4K
$0
$0
$0
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$2M−$1M$0$1M$2MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$12.4K−$1.1M
FY24$3.5K−$1.8M
FY23$604.7K−$1.2M
FY22$104.3K−$1.2M
FY21$1.2M−$1.5M
FY20$0−$711.8K
FY19$0−$148K
FY18$0−$144K
FY17$0−$224K
FY16$0−$130K
FY15$0−$116K
FY14$0−$106K
FY13-−$103K
FY12$0−$84K
FY11$0−$110K
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−60000%−40000%−20000%0%20000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2566.1%−9614.6%−8736.7%
FY2476.3%−51006.3%−51171.4%
FY2369.3%−197.6%−197.6%
FY2250.5%−1155.7%−1155.5%
FY2165.9%−124%−124%
FY20---
FY19---
FY18---
FY17---
FY16---
FY15---
FY14---
FY13---
FY12---
FY11---
Free cash flowOperating cash flow minus capital expenditure
−$2M−$1.5M−$1M−$500K$0$500KFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22−$601K
FY21−$1.6M
FY20$58.6K
FY19-
FY18-
FY17-
FY16-
FY15-
FY14-
FY13-
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Yubo International Biotech
  • Healthcare median
−60000%−40000%−20000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearYubo International BiotechHealthcare median
FY25−8736.7%−30.6%
FY24−51171.4%−47%
FY23−197.6%−58%
FY22−1155.5%−80.4%
FY21−124%−71.9%
FY20-−62.2%
FY19-−46.3%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−38.4%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%
FY11-−27.9%